The recent publication “PD-L1 Immunohistochemistry Comparability Studying Real-Life Clinical Samples: Results of Blueprint Phase 2 Project” reports on the exercise of comparing the staining and scoring of the well-known commercial PD-L1 clones.

More

The HistoGeneX molecular team performs more than 11,000 DNA and RNA extractions each year manually. Yes, manually.

More

Neo-adjuvant immunotherapy in bladder cancer. Complete pathological response in bladder wall is related with the PDL1 status and opens opportunities to understand biological mechanism of action.

More

Perhaps Even up to Half the Amount?

More

Announcing HistoGeneX's new partnership with the BluePrint 2 Initiative.

More